0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurodegenerative Diseases Drug Market Research Report 2023
Published Date: June 2023
|
Report Code: QYRE-Auto-33M1920
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neurodegenerative Diseases Drug Market Research Report 2023

Code: QYRE-Auto-33M1920
Report
June 2023
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neurodegenerative Diseases Drug Market

Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional. 
The global Neurodegenerative Diseases Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Neurodegenerative Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Neurodegenerative Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Neurodegenerative Diseases Drug in Multiple Sclerosis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Neurodegenerative Diseases Drug include Biogen, Pfizer, Roche, Novartis, Sanofi, Teva Pharmaceuticals, Orion Pharma Ltd, UCB S.A and ACADIA Pharmaceuticals Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Drug.
The Neurodegenerative Diseases Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Neurodegenerative Diseases Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Neurodegenerative Diseases Drug Market Report

Report Metric Details
Report Name Neurodegenerative Diseases Drug Market
Segment by Type
  • By Drug Class
  • Immunomodulator
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others
  • By Route of Administration
  • Oral
  • Injection
  • Transdermal
Segment by Application
  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer’s Disease
  • Spinal Muscular Atrophy (SMA)
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Biogen, Pfizer, Roche, Novartis, Sanofi, Teva Pharmaceuticals, Orion Pharma Ltd, UCB S.A, ACADIA Pharmaceuticals Inc., Lundbeck Pharmaceuticals Italy S.p.A., Mitsubishi Tanabe Pharma America
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neurodegenerative Diseases Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis By Drug Class
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate By Drug Class: 2018 VS 2022 VS 2029
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’s Disease
1.3.4 Alzheimer’s Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2018-2029)
2.2 Neurodegenerative Diseases Drug Growth Trends by Region
2.2.1 Global Neurodegenerative Diseases Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neurodegenerative Diseases Drug Historic Market Size by Region (2018-2023)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Region (2024-2029)
2.3 Neurodegenerative Diseases Drug Market Dynamics
2.3.1 Neurodegenerative Diseases Drug Industry Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2018-2023)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2018-2023)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2022
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2018-2023)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2024-2029)
5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2018-2023)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2018-2029)
6.2 North America Neurodegenerative Diseases Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neurodegenerative Diseases Drug Market Size by Country (2018-2023)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2018-2029)
7.2 Europe Neurodegenerative Diseases Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neurodegenerative Diseases Drug Market Size by Country (2018-2023)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2018-2029)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2018-2029)
9.2 Latin America Neurodegenerative Diseases Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Country (2018-2023)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2018-2029)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Detail
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Detail
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Detail
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Detail
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2018-2023)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Immunomodulator
    Table 3. Key Players of Interferons
    Table 4. Key Players of Decarboxylase Inhibitors
    Table 5. Key Players of Dopamine Agonists
    Table 6. Key Players of Others
    Table 7. Global Neurodegenerative Diseases Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Neurodegenerative Diseases Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 9. Global Neurodegenerative Diseases Drug Market Size by Region (2018-2023) & (US$ Million)
    Table 10. Global Neurodegenerative Diseases Drug Market Share by Region (2018-2023)
    Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 12. Global Neurodegenerative Diseases Drug Market Share by Region (2024-2029)
    Table 13. Neurodegenerative Diseases Drug Market Trends
    Table 14. Neurodegenerative Diseases Drug Market Drivers
    Table 15. Neurodegenerative Diseases Drug Market Challenges
    Table 16. Neurodegenerative Diseases Drug Market Restraints
    Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2018-2023) & (US$ Million)
    Table 18. Global Neurodegenerative Diseases Drug Market Share by Players (2018-2023)
    Table 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2022)
    Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2022
    Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2018-2023)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
    Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2018-2023) & (US$ Million)
    Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2018-2023)
    Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2024-2029)
    Table 30. Global Neurodegenerative Diseases Drug Market Size by Application (2018-2023) & (US$ Million)
    Table 31. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2018-2023)
    Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 33. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2024-2029)
    Table 34. North America Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. North America Neurodegenerative Diseases Drug Market Size by Country (2018-2023) & (US$ Million)
    Table 36. North America Neurodegenerative Diseases Drug Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Europe Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Europe Neurodegenerative Diseases Drug Market Size by Country (2018-2023) & (US$ Million)
    Table 39. Europe Neurodegenerative Diseases Drug Market Size by Country (2024-2029) & (US$ Million)
    Table 40. Asia-Pacific Neurodegenerative Diseases Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2018-2023) & (US$ Million)
    Table 42. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2024-2029) & (US$ Million)
    Table 43. Latin America Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Latin America Neurodegenerative Diseases Drug Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Latin America Neurodegenerative Diseases Drug Market Size by Country (2024-2029) & (US$ Million)
    Table 46. Middle East & Africa Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 47. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2018-2023) & (US$ Million)
    Table 48. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2024-2029) & (US$ Million)
    Table 49. Biogen Company Detail
    Table 50. Biogen Business Overview
    Table 51. Biogen Neurodegenerative Diseases Drug Product
    Table 52. Biogen Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 53. Biogen Recent Development
    Table 54. Pfizer Company Detail
    Table 55. Pfizer Business Overview
    Table 56. Pfizer Neurodegenerative Diseases Drug Product
    Table 57. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 58. Pfizer Recent Development
    Table 59. Roche Company Detail
    Table 60. Roche Business Overview
    Table 61. Roche Neurodegenerative Diseases Drug Product
    Table 62. Roche Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 63. Roche Recent Development
    Table 64. Novartis Company Detail
    Table 65. Novartis Business Overview
    Table 66. Novartis Neurodegenerative Diseases Drug Product
    Table 67. Novartis Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 68. Novartis Recent Development
    Table 69. Sanofi Company Detail
    Table 70. Sanofi Business Overview
    Table 71. Sanofi Neurodegenerative Diseases Drug Product
    Table 72. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 73. Sanofi Recent Development
    Table 74. Teva Pharmaceuticals Company Detail
    Table 75. Teva Pharmaceuticals Business Overview
    Table 76. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
    Table 77. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 78. Teva Pharmaceuticals Recent Development
    Table 79. Orion Pharma Ltd Company Detail
    Table 80. Orion Pharma Ltd Business Overview
    Table 81. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
    Table 82. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 83. Orion Pharma Ltd Recent Development
    Table 84. UCB S.A Company Detail
    Table 85. UCB S.A Business Overview
    Table 86. UCB S.A Neurodegenerative Diseases Drug Product
    Table 87. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 88. UCB S.A Recent Development
    Table 89. ACADIA Pharmaceuticals Inc. Company Detail
    Table 90. ACADIA Pharmaceuticals Inc. Business Overview
    Table 91. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
    Table 92. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 93. ACADIA Pharmaceuticals Inc. Recent Development
    Table 94. Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
    Table 95. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
    Table 96. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
    Table 97. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 98. Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
    Table 99. Mitsubishi Tanabe Pharma America Company Detail
    Table 100. Mitsubishi Tanabe Pharma America Business Overview
    Table 101. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
    Table 102. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2018-2023) & (US$ Million)
    Table 103. Mitsubishi Tanabe Pharma America Recent Development
    Table 104. Research Programs/Design for This Report
    Table 105. Key Data Information from Secondary Sources
    Table 106. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Diseases Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Neurodegenerative Diseases Drug Market Share by Type: 2022 VS 2029
    Figure 3. Immunomodulator Features
    Figure 4. Interferons Features
    Figure 5. Decarboxylase Inhibitors Features
    Figure 6. Dopamine Agonists Features
    Figure 7. Others Features
    Figure 8. Global Neurodegenerative Diseases Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 9. Global Neurodegenerative Diseases Drug Market Share by Application: 2022 VS 2029
    Figure 10. Multiple Sclerosis Case Studies
    Figure 11. Parkinson’s Disease Case Studies
    Figure 12. Alzheimer’s Disease Case Studies
    Figure 13. Spinal Muscular Atrophy (SMA) Case Studies
    Figure 14. Others Case Studies
    Figure 15. Neurodegenerative Diseases Drug Report Years Considered
    Figure 16. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 17. Global Neurodegenerative Diseases Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 18. Global Neurodegenerative Diseases Drug Market Share by Region: 2022 VS 2029
    Figure 19. Global Neurodegenerative Diseases Drug Market Share by Players in 2022
    Figure 20. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2022)
    Figure 21. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2022
    Figure 22. North America Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. North America Neurodegenerative Diseases Drug Market Share by Country (2018-2029)
    Figure 24. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Europe Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Europe Neurodegenerative Diseases Drug Market Share by Country (2018-2029)
    Figure 28. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. France Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Nordic Countries Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Region (2018-2029)
    Figure 36. China Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. India Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Latin America Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Latin America Neurodegenerative Diseases Drug Market Share by Country (2018-2029)
    Figure 44. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Country (2018-2029)
    Figure 48. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 50. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 51. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 52. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 53. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 54. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 55. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 56. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 57. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 58. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 59. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 60. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2018-2023)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS